LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Lineage Cell Therapeutics Inc (LCTX) does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has promising developments and a recent price target increase, the technical indicators, options data, and financial performance do not strongly support immediate action. Holding off for more favorable signals or developments is recommended.
The MACD is negative and contracting, RSI is neutral at 43.138, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 1.554, with key resistance at 1.665 and support at 1.443.
The company has a differentiated manufacturing approach for its corneal endothelial cell therapy, potentially addressing a large market (2M-6M U.S. patients). Analyst B. Riley raised the price target to $4 from $3, maintaining a Buy rating.
No recent news or significant trading trends from hedge funds or insiders. Financial performance shows a significant drop in net income (-126% YoY) and EPS (-100% YoY), despite revenue growth. Technical indicators and options data do not signal strong upward momentum.
In 2025/Q4, revenue increased by 130.40% YoY to $6.6M, but net income dropped by -126% YoY to $851K, and EPS fell to 0 (-100% YoY). Gross margin improved by 4.62% YoY to 99%.
B. Riley raised the price target to $4 from $3 and maintained a Buy rating, citing the potential of the company's corneal endothelial cell therapy and its scalable manufacturing approach.
